Methods for detecting and inhibiting angiogenesis
View Patent ↗The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition.
1. A method of reducing or inhibiting angiogenesis in a tissue, comprising administering an anti-α5β1 antibody which interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue.
2. The method of claim 1 , wherein the tissue is in an individual.
3. The method of claim 2 , wherein the individual is a human.
4. The method of claim 1 , wherein the ligand is fibronectin.
5. The method of claim 1 , wherein the tissue comprises ocular tissue.
6. The method of claim 5 , wherein the ocular tissue is selected from the group consisting of retina, macula, and cornea.
7. The method of claim 1 , wherein the tissue comprises a neoplasm.
8. The method of claim 7 , wherein the neoplasm is a malignant neoplasm.
9. The method of claim 8 , wherein the malignant neoplasm is a metastatic malignant neoplasm.
10. The method of claim 8 , wherein the malignant neoplasm is selected from the group consisting of breast, colon, lung and prostate cancer.
11. The method of claim 1 , wherein the agent is administered intravenously.
12. The method of claim 5 , wherein the ocular tissue is associated with a pathological condition.
13. The method of claim 12 , wherein the pathological condition is selected from the group consisting of diabetic retinopathy and macular degeneration by neovascularization.